Company news

Ascendis Pharma A/S news in 2025

Ascendis Pharma A/S's news releases, calls and decks from 2025, newest first.

View company

Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

November 25, 2025

Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics

November 17, 2025

Ascendis Pharma Reports Third Quarter 2025 Financial Results

November 12, 2025

New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

November 7, 2025

Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025

November 5, 2025

3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025

November 3, 2025

Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia

October 8, 2025

Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025

September 2, 2025

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference

August 28, 2025

Ascendis Pharma Reports Second Quarter 2025 Financial Results

August 7, 2025

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

July 31, 2025

FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency

July 28, 2025

New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life

July 14, 2025

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025

July 7, 2025

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

June 9, 2025

FDA Accepts TransCon® CNP NDA for Priority Review

June 2, 2025

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

May 13, 2025

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

May 12, 2025

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

May 5, 2025

Ascendis Pharma Reports First Quarter 2025 Financial Results

May 1, 2025

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

March 30, 2025

First and only treatment for chronic hypoparathyroidism approved in Australia

February 19, 2025

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

February 11, 2025

Calls in 2025

Decks in 2025